We transcend borders, time zones, and especially the status quo to develop therapies that are more accessible to people around the world.

Learn More

Putting Patients First

Learn more about how we are working to discover and develop innovative medicines that are more accessible and affordable to patients around the world.

Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More
doctor_and_patient

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More
people_walking

Our Commitment to Patients

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More
elder_women

BeiGene News

February 29, 2024

BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Read more

February 28, 2024

BeiGene to Present at Upcoming Investor Conferences

Read more

February 27, 2024

BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

Read more

February 26, 2024

BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Read more

February 26, 2024

BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Read more

January 23, 2024

BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors

Read more